Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Nivolumab
Synonyms
Therapy Description

Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 115 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MSH6 negative colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative cholangiocarcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 1 complete response and 1 stable disease in two patients with cholangiocarcinoma (PMID: 31765263; NCT02465060). 31765263
BRAF V600K melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828). 30630828
CD274 over exp lung non-small cell carcinoma predicted - sensitive Nivolumab Clinical Study - Meta-analysis Actionable In a meta-analysis, treatment with immune checkpoint inhibitors including Tecentriq (atezolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) resulted in improved progression-free survival (HR=0.41, p<0.001) and overall survival (HR=0.62, p=0.006) in non-small cell lung cancer patients with high CD274 (PD-L1) expression compared to patients with low CD274 (PD-L1) expression (PMID: 31290993). 31290993
CD274 over exp lung non-small cell carcinoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, non-small cell lung carcinoma patients with a CD274 (PD-L1) TPS of >=50% treated with Opdivo (nivolumab) achieved an overall response rate of 45.8% vs. 15.9% (p=0.002) and a median progression-free survival of 8.1 months vs. 2.2 months (HR=0.54; 95% CI: 0.33-0.90; p=0.02), and demonstrated an overall survival benefit (HR=0.44; 95% CI: 0.23-0.84; p=0.01) compared to patients with a TPS of < 50% (PMID: 32955570). 32955570
PMS2 negative rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
BRAF mut IDH1 wild-type glioblastoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). 30742119
CD274 positive melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). 29973670
PTEN dec exp melanoma decreased response Nivolumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196). 26645196
MSH2 negative endometrial adenocarcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 2 complete responses and 2 partial responses in patients with endometrioid endometrial adenocarcinoma (n=13) (PMID: 31765263; NCT02465060). 31765263
POLE P286R colorectal cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in a complete response in a colorectal cancer patient harboring POLE P286R, along with high tumor mutational burden and CD8-positive high tumor infiltrating lymphocytes, and a partial response in a different colorectal cancer patient also harboring POLE P286R, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
CD274 positive transitional cell carcinoma predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (CheckMate 275), Opdivo (nivolumab) treatment in platinum-resistant urothelial carcinoma patients resulted in an objective response rate (ORR) of 20.7% (56/270), a median progression-free survival (mPFS) of 1.9 mo., and a median overall survival (mOS) of 8.6 mo., and patients with CD274 (PD-L1)-positive tumors (IHC>=1% compared to <1%) had improved ORR (25.8%, 32/124 v 16.4%, 24/146), mPFS (3.5 v 1.9 mo), and mOS (11.9 v 6.0 mo) (PMID: 32532789; NCT02387996). 32532789
CD274 positive transitional cell carcinoma predicted - sensitive Nivolumab Phase III Actionable In a Phase III trial (CheckMate-274), adjuvant Opdivo (nivolumab) treatment significantly improved the percentage of patients who were alive and disease-free at 6 months (74.5% vs 55.7%, HR 0.55, P<0.001) and median recurrence-free survival (22.9 vs 13.7 mo) compared to placebo in patients with high-risk urothelial carcinoma with a PD-L1 expression level of 1% or more (PMID: 34077643; NCT02632409). 34077643
MLH1 negative endometrial cancer sensitive Nivolumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
PBRM1 E291* clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 E291* (PMID: 29301960). 29301960
MSH2 negative cholangiocarcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 1 complete response and 1 stable disease in two patients with cholangiocarcinoma (PMID: 31765263; NCT02465060). 31765263
CD274 positive esophagus squamous cell carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). detail... 35914638
B2M negative melanoma predicted - resistant Nivolumab Case Reports/Case Series Actionable In a clinical case study, loss of B2m protein expression was identified during and after disease progression in a melanoma patient harboring B2M loss of heterozygosity (LOH), whose disease briefly responded to Opdivo (nivolumab) treatment (PMID: 29070816). 29070816
MLH1 negative rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
POLE P286R endometrial cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in stable disease in an endometrial cancer patient harboring POLE P286R, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
POLE S459F colorectal cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in a durable partial response in a colorectal cancer patient harboring POLE S459F, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
MLH1 negative small intestine adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH2 negative rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative endometrial adenocarcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 2 complete responses and 2 partial responses in patients with endometrioid endometrial adenocarcinoma (n=13) (PMID: 31765263; NCT02465060). 31765263
MSH2 negative Advanced Solid Tumor predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), a median progression-free survival (PFS) of 6.3 mo, a 6-month PFS rate of 51.3%, and a median overall survival of 17.3 months (PMID: 31765263; NCT02465060). 31765263
FGFR3 mutant transitional cell carcinoma no benefit Nivolumab Phase II Actionable In a Phase II trial (CheckMate 275), Opdivo (nivolumab) (n=270) treatment resulted in similar response rate (20% vs 21%, p=0.2) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788). 31272788
POLD1 inact mut colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as systemic therapy for patients with advanced or metastatic colon cancer harboring POLD1 inactivating mutations (NCCN.org). detail...
NRAS mutant melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670). 29973670
MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 colorectal carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical case study, Opdivo (nivolumab) treatment resulted in stable disease lasting four months in a colorectal carcinoma patient harboring MSH6 F1088Lfs*5, Y1256*, and A1320Sfs*5 (PMID: 35739269). 35739269
PTEN mutant gastrointestinal system cancer decreased response Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with MSI high, dMMR gastrointestinal tumors including gastric (n=18), colorectal (n=17), cholangiocarcinoma (n=5), small intestine (n=2), pancreatic (n=2), and duodenal cancer (n=1) harboring PTEN mutations demonstrated a decreased objective response rate (21.4 vs 54.8%), overall survival (15.2 vs 25.7 mo), and progression-free survival (4.3 vs 15.6 mo) compared to PTEN-wild-type patients when treated with Keytruda (pembrolizumab) or Opdivo (nivolumab) (PMID: 33926917). 33926917
POLD1 inact mut rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as systemic therapy for patients with advanced or metastatic rectal cancer harboring POLD1 inactivating mutations (NCCN.org). detail...
POLE inact mut colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as systemic therapy for patients with advanced or metastatic colon cancer harboring POLE inactivating mutations (NCCN.org). detail...
CD274 positive stomach cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastric cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). detail... 35914639
CD274 positive stomach cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with first-line chemotherapy including fluoropyrimidine and oxaliplatin, is included in guidelines as preferred first-line therapy for patients with gastric cancer expressing PD-L1 (CD274, CPS>=5), and without ERBB2 (HER2) overexpression (category 1), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <5) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org). detail...
CD274 positive renal cell carcinoma predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment in patients with CD274 (PD-L1)-positive treatment-naive advanced clear cell renal cell carcinoma resulted in an objective response rate (ORR) 50% (8/16) in patients with CD274 (PD-L1) expression between 1% to 20% and an ORR of 75% (6/8), median progression-free survival (PFS) of 20.6 months, and 1-year PFS rate of 75% in patients with CD274 (PD-L1) expression of 20% or higher (PMID: 35442713; NCT03117309). 35442713
CD274 neg MSH6 W628* glioblastoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical case study, Opdivo (nivolumab) treatment resulted in a 60% reduction of tumor size and durable clinical response that was still ongoing after 10 months in a pediatric patient with refractory glioblastoma that was CD274 (PD-L1) negative, the patient was also diagnosed with constitutional mismatch repair-deficiency (CMMRD) syndrome due to biallelic MSH6 W628* mutation (PMID: 30104292). 30104292
MLH1 negative colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
PBRM1 Y331* clear cell renal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in complete response in a patient with renal clear cell carcinoma harboring PBRM1 Y331* (PMID: 29301960). 29301960
PMS2 negative endometrial carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). detail...
ARID1A mutant bladder urothelial carcinoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, metastatic urothelial carcinoma patients from the CheckMate275 trial harboring an ARID1A mutation (n=39) demonstrated a greater overall survival (11.4 mo vs 6.0 mo; P=0.03) compared to patients with wild-type ARID1A (n=100) when treated with Opdivo (nivolumab) (PMID: 32554706; NCT02387996). 32554706
MDM2 amp endometrial stromal sarcoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical case study, a patient with endometrial stromal sarcoma that harbored MDM2 amplification quickly progressed after receiving Opdivo (nivolumab), resulted in new abdominal metastasis and a 242% increase of existing liver metastasis size within 1.5 months of treatment (PMID: 28351930). 28351930
MSH2 negative endometrial cancer sensitive Nivolumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
BRAF wild-type melanoma predicted - sensitive Nivolumab Phase III Actionable In a Phase III trial (CheckMate-066), Opdivo (nivolumab) treatment resulted in improved overall survival and response compared to treatment with Deticene (dacarbazine) in melanoma patients with wild-type BRAF, including a 3-year overall survival (OS) rate of 51.2% vs. 21.6%, a median OS of 37.5 months vs. 11.2 months, a complete response in 19% (40/210) vs. 1.4% (3/208), and a partial response in 23.8% (50/210) vs. 13% (27/208), respectively (PMID: 30422243; NCT01721772). 30422243
POLE inact mut Advanced Solid Tumor predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in an objective response rate (ORR) of 38% (7/19; all partial responses) and a disease control rate (DCR) of 58% (11/19) at 12 weeks in patients with advanced solid tumors harboring a POLE mutation, and among assessable patients with an inactivating POLE mutation, along with high tumor mutational burden, treatment resulted in an ORR of 46% (5/11) and a DCR of 73% (8/11) (PMID: 35398880; NCT03012581). 35398880
PBRM1 K154fs clear cell renal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 K154fs (PMID: 29301960). 29301960
BRAF V600E melanoma decreased response Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828). 30630828
MSH2 negative colorectal cancer sensitive Nivolumab FDA approved Actionable In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). 28734759 detail... detail...
PBRM1 K135fs clear cell renal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in stable disease in a patient with renal clear cell carcinoma harboring PBRM1 K135fs (PMID: 29301960). 29301960
PBRM1 W141_L145delinsC clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 W141_L145delinsC (PMID: 29301960). 29301960
POLE D435G colorectal cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in a partial response in a colorectal cancer patient harboring POLE D435G (PMID: 35398880; NCT03012581). 35398880
MSH6 negative colorectal cancer sensitive Nivolumab FDA approved Actionable In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). 28734759 detail... detail...
PMS2 negative small intestine adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
POLE G330R biliary tract cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in stable disease in a biliary tract cancer patient harboring POLE G330R (PMID: 35398880; NCT03012581). 35398880
PBRM1 N609fs clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 N609fs (PMID: 29301960). 29301960
TP53 mutant lung non-small cell carcinoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). 31097096
PBRM1 R941fs clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 R941fs (PMID: 29301960). 29301960
PBRM1 mutant clear cell renal cell carcinoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, PBRM1 truncating mutations were associated with response to Opdivo (nivolumab) with 39% (15/38) of responding patients harboring PBRM1 mutations vs 22% (16/74) of non-responders, as well as clinical benefit (p=0.0497), increased progression-free survival (HR=0.67), and overall survival (HR=0.65) in post-hoc analysis of archival samples from a Phase III clinical trial of clear cell renal cell carcinoma patients (PMID: 31486842). 31486842
PBRM1 inact mut clear cell renal cell carcinoma sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, renal clear cell carcinoma patients harboring PBRM1 loss-of-function mutations demonstrated improved response to immune checkpoint therapies including Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), and Tecentriq (atezolizumab), potentially due to the distinct expression profile of immune-related genes in these patients (PMID: 29301960). 29301960
PTEN positive melanoma sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196). 26645196
PBRM1 K621* clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 K621* (PMID: 29301960). 29301960
CD274 amp basal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic basal cell carcinoma harboring CD274 amplification and a high mutational burden was sensitive to treatment with Opdivo (nivolumab), demonstrating reduced lesion size after two months of treatment and a nearly complete regression of liver lesions after four months of treatment (PMID: 27942391). 27942391
PBRM1 Y608fs clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 Y608fs (PMID: 29301960). 29301960
CD274 positive glioblastoma no benefit Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). 30742119
CD274 positive lung non-small cell carcinoma no benefit Nivolumab Phase III Actionable In a Phase III trial, treatment with Opdivo (nivolumab) did not result in longer median progression-free survival (PFS) or overall survival (OS) than chemotherapy treatment in patients with stage IV or recurrent non-small cell lung cancer with PD-L1 (CD274) expression of greater than 5%, resulting in a median PFS of 4.2 mo vs. 5.9 mo with chemotherapy (HR=1.15; 95% CI 0.91-1.45; p=0.25) and a median OS of 14.4 mo vs. 13.2 mo with chemotherapy (HR=1.15; 95% CI 0.80-1.30) (PMID: 28636851; NCT02041533). 28636851
PBRM1 N463fs clear cell renal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 N463fs (PMID: 29301960). 29301960
POLE inact mut rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as systemic therapy for patients with advanced or metastatic rectal cancer harboring POLE inactivating mutations (NCCN.org). detail...
CD274 positive lung non-squamous non-small cell carcinoma sensitive Nivolumab Phase III Actionable In a Phase III trial (CheckMate 057), Opdivo (nivolumab) treatment demonstrated greater overall survival, progression-free survival, and objective response rate at all CD274 (PD-L1) expression levels analyzed (1% or more, 5% or more, 10% and more) in nonsquamous non-small cell lung carcinoma patients (PMID: 26412456; NCT01673867). 26412456
MSH2 negative small intestine adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
CD274 amp lung non-small cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical case study, a CD274 (PD-L1) amplified non-small cell lung carcinoma patient treated with Opdivo (nivolumab) achieved stable disease with a 20% reduction in tumor growth and a progression-free survival of 9.7 months (PMID: 32955570). 32955570
CD274 amp lung non-small cell carcinoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, treatment with Opdivo (nivolumab) did not result in a significant overall response rate (ORR) in non-small cell lung cancer (NSCLC) patients with a CD274 copy number gain (CNG; amplification and polysomy) vs patients without a CNG (28.1% vs. 17.9%; p=0.22), but NSCLC patients with CD274 amplification demonstrated an ORR of 80% (4/5), a 1-year progression-free survival of 80%, a 1-year overall survival of 100%, and the median duration of response was not yet reached (PMID: 32955570). 32955570
BRAF V600E lung non-small cell carcinoma not predictive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). 29723688
MLH1 negative endometrial carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). detail...
MSH6 negative endometrial cancer sensitive Nivolumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
IDH1 wild-type PTEN mut glioblastoma resistant Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119). 30742119
POLE A463V endometrial cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in stable disease in a patient with endometrial cancer harboring POLE A463V, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
PMS2 negative colorectal cancer sensitive Nivolumab FDA approved Actionable In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). 28734759 detail... detail...
POLE N363K endometrial cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in stable disease in an endometrial cancer patient harboring POLE N363K, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
MLH1 negative Advanced Solid Tumor predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), a median progression-free survival (PFS) of 6.3 mo, a 6-month PFS rate of 51.3%, and a median overall survival of 17.3 months (PMID: 31765263; NCT02465060). 31765263
MSH2 negative colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
CD274 positive esophageal cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated esophageal cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). 35914639 detail...
MSH6 negative small intestine adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
PBRM1 G2fs clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 G2fs (PMID: 29301960). 29301960
CD274 positive gastroesophageal junction adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastroesophageal junction adenocacinoma expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). detail... 35914639
CD274 positive biliary tract cancer sensitive Nivolumab Phase II Actionable In a Phase II trial, baseline CD274 (PD-L1) expression was associated with increased median progression-free survival (PFS) in biliary tract cancer patients treated with Opdivo (nivolumab) compared to patients without CD274 (PD-L1) expression, with a median PFS of 19.8 months vs 2.4 months (P=0.0001) and 12-month PFS rate of 61% vs 5%, respectively (PMID: 36252287; NCT02829918). 36252287
PMS2 negative endometrial cancer sensitive Nivolumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
ALK rearrange lung non-small cell carcinoma no benefit Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
ALK rearrange lung non-small cell carcinoma no benefit Nivolumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
BRAF mut CD274 pos lung non-small cell carcinoma not predictive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, BRAF mutant non-small cell lung cancer patients with CD274 (PD-L1) expression >/= 50% did not show a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab) when compared to BRAF mutant patients with CD274 (PD-L1) expression, 0-49%, demonstrating an objective response rate of 36% (4/11) vs 14% (1/7) (p=0.59) and median progression-free survival of 5.3 mo vs 2.2 mo (p=0.73) (PMID: 29723688). 29723688
CD274 positive malignant spindle cell melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). 29320474
CD274 positive cervical cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
POLE V411L endometrial cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in a partial response in two patients with endometrial cancer harboring POLE V411L, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
POLE V464A colorectal cancer predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a Phase II trial, Opdivo (nivolumab) resulted in a durable complete response in a colorectal cancer patient harboring POLE V464A, along with high tumor mutational burden (PMID: 35398880; NCT03012581). 35398880
MSH6 negative endometrial carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). detail...
MSH2 negative endometrial carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). detail...
PMS2 negative colon cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
PBRM1 A249fs clear cell renal cell carcinoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 A249fs (PMID: 29301960). 29301960
PBRM1 S681R clear cell renal cell carcinoma predicted - sensitive Nivolumab Case Reports/Case Series Actionable In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 S681R (PMID: 29301960). 29301960
MSH6 negative rectum cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative colorectal cancer sensitive Nivolumab FDA approved Actionable In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). detail... 28734759 detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03918252 Phase II Ipilimumab + Nivolumab Nivolumab Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Recruiting USA 0
NCT03470922 Phase II Nivolumab + Relatlimab Nivolumab A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Completed USA 0
NCT05150236 Phase II Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) Active, not recruiting AUS 0
NCT02743494 Phase III Nivolumab Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT04606316 Phase I Nivolumab Ipilimumab + Nivolumab Surgical Nivolumab And Ipilimumab For Recurrent GBM Active, not recruiting USA 0
NCT04128020 Phase I Azacitidine + Nivolumab Nivolumab Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Withdrawn 0
NCT03465592 Phase Ib/II Nivolumab Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma Recruiting USA 0
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Completed USA 0
NCT03712202 Phase II Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma Active, not recruiting USA 0
NCT04612530 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Nivolumab IMO-2125 + Nivolumab PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer Recruiting 1
NCT05310591 Phase Ib/II Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) Recruiting FRA 0
NCT04581382 Phase I Pembrolizumab Nivolumab Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma Active, not recruiting USA 0
NCT04157985 Phase III Nivolumab Ipilimumab Pembrolizumab Atezolizumab Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06054555 Phase III ABP 206 Nivolumab A Study to Evaluate ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma Recruiting USA | ITA | FRA | ESP | CAN 9
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed USA 0
NCT03238365 Phase I Nivolumab + Tadalafil Nivolumab Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Completed USA 0
NCT05111574 Phase II Nivolumab Cabozantinib + Nivolumab Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Recruiting USA | CAN 0
NCT04050462 Phase II BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients Active, not recruiting USA 0
NCT02985554 Phase I Nivolumab Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies Terminated USA 0
NCT03068455 Phase III Nivolumab Ipilimumab Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT05491616 Phase II Nivolumab Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study (SANO-3) Recruiting 1
NCT03743766 Phase II Relatlimab Nivolumab + Relatlimab Nivolumab Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting Active, not recruiting USA 0
NCT03635983 Phase III Nivolumab Nivolumab + NKTR-214 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT06112314 Phase III Nivolumab IMC-F106C + Nivolumab Nivolumab + Relatlimab IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) Recruiting USA | AUS 0
NCT04007588 Phase II Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Withdrawn USA 0
NCT04594811 Phase II Nivolumab Nivolumab + NT-I7 NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma Terminated USA 1
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA | ESP 0
NCT04062656 Phase II Nivolumab + Relatlimab Nivolumab Docetaxel + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (IMAGINE) Active, not recruiting DEU 0
NCT04131621 Phase II Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) Unknown status DEU 0
NCT02339571 Phase II Sargramostim Nivolumab Ipilimumab Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting USA 0
NCT06019130 Phase II Cisplatin + Fluorouracil Cisplatin + Gemcitabine Nivolumab Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo) Recruiting DEU 0
NCT03557359 Phase II Nivolumab Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Active, not recruiting USA 0
NCT04620200 Phase II Ipilimumab + Nivolumab Nivolumab Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) Recruiting 1
NCT03873402 Phase III Nivolumab Ipilimumab + Nivolumab An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Active, not recruiting USA | ITA | FRA | ESP | AUT 9
NCT03055013 Phase III Nivolumab Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) Active, not recruiting USA | CAN 1
NCT03838263 Phase II Nivolumab Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer (IMMUNEBOOST) Active, not recruiting FRA 0
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Active, not recruiting USA 0
NCT03302247 Phase II Nivolumab Gemcitabine + Nivolumab Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy Terminated USA 0
NCT02736123 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Withdrawn USA 0
NCT02500797 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma Completed USA 0
NCT05317000 Phase I Azacitidine Azacitidine + Nivolumab Nivolumab 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC Recruiting USA 0
NCT03371992 Phase I Nivolumab Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) Unknown status USA 0
NCT04204837 Phase II Nivolumab + Relatlimab Nivolumab Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Recruiting AUT 0
NCT02775292 Phase I Aldesleukin + Cyclophosphamide + Fludarabine Nivolumab NY-ESO-1 peptide vaccine Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 Completed USA 0
NCT03637543 Phase II Nivolumab Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Active, not recruiting USA 0
NCT03630640 Phase II Nivolumab Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) Active, not recruiting FRA 0
NCT03543189 Phase Ib/II Nivolumab Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Active, not recruiting USA 0
NCT04949113 Phase III Nivolumab Ipilimumab + Nivolumab Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) Active, not recruiting USA | AUS 1
NCT02475382 Expanded access Nivolumab Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) No longer available CAN 1
NCT04695977 Phase II Nivolumab Nivolumab + Vidutolimod CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma Active, not recruiting USA 0
NCT02467361 Phase Ib/II Nivolumab Pembrolizumab Ipilimumab Napabucasin A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers Completed USA 0
NCT01658878 Phase I Nivolumab Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 6
NCT05112549 Phase I Nivolumab Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1) Recruiting DEU 0
NCT03604978 Phase Ib/II Ipilimumab + Nivolumab Nivolumab Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma Recruiting USA 0
NCT03021993 Phase II Nivolumab Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Completed USA 0
NCT01621490 Phase I Ipilimumab Nivolumab PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) Completed USA | ESP 1
NCT06101134 Phase II BMS-986298 Nivolumab + Relatlimab + rHuPH20 Nivolumab and relatlimab-rmbw Nivolumab A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations Recruiting USA | ITA | ESP 3
NCT04173325 Phase I Nivolumab Irinotecan + Nivolumab Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer Terminated USA 0
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02632409 Phase III Nivolumab A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04810078 Phase III Nivolumab Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T) Recruiting USA | ITA | FRA | ESP 13
NCT04019964 Phase II Nivolumab Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Recruiting USA 0
NCT02387996 Phase II Nivolumab A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer Completed USA | ITA | ESP | DEU | BEL | AUS 5
NCT03768531 Phase II Cabiralizumab + Nivolumab Nivolumab Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer Withdrawn 0
NCT03663166 Phase Ib/II Cisplatin + Ipilimumab + Pemetrexed Disodium Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Active, not recruiting USA 0
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA 0
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03634800 Phase II Nivolumab Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) Terminated USA 0
NCT03406247 Phase II Ipilimumab + Nivolumab Nivolumab Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) Recruiting FRA 0
NCT04323046 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Recruiting USA | AUS 2
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma Terminated USA 0
NCT02914405 Phase I Dinutuximab beta + Nivolumab Nivolumab Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (MiniVan) Recruiting USA | GBR 0
NCT02713867 Phase III Nivolumab A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) Completed USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 0
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Active, not recruiting USA 0
NCT03461952 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) Terminated USA | CAN 0
NCT02498600 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT01176474 Phase I NY-ESO-1 peptide vaccine Ipilimumab Nivolumab A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Completed USA 0
NCT02257528 Phase II Nivolumab Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting USA 0
NCT03850067 Phase Ib/II Carboplatin + CC-90011 + Etoposide CC-90011 + Cisplatin + Etoposide Nivolumab A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer Active, not recruiting ITA | FRA | ESP 0
NCT03143270 Phase I Nivolumab A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Active, not recruiting USA 0
NCT02314169 Phase II Nivolumab Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Active, not recruiting USA | CAN 0
NCT03121417 Phase II Nivolumab Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer Withdrawn USA 0
NCT03668119 Phase II Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT03580408 Phase II Nivolumab + Vinblastine Nivolumab Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma Completed FRA | BEL 0
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT03529890 Phase II Nivolumab Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) Unknown status DEU 0
NCT02696993 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT05148546 Phase II Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) Recruiting GBR 1
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04013542 Phase I Ipilimumab + Nivolumab Nivolumab Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Active, not recruiting USA 0
NCT03405155 Phase II Nivolumab Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery Active, not recruiting USA 0
NCT02451982 Phase Ib/II Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer Recruiting USA 0
NCT03337919 Phase II Nivolumab ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE) Active, not recruiting GBR 0
NCT03090737 Phase II Nivolumab Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) Completed USA | CAN 3
NCT02864381 Phase II Nivolumab Andecaliximab + Nivolumab GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed USA | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT04361058 Phase I Nivolumab Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Withdrawn USA 0
NCT03999749 Phase II Nivolumab Ipilimumab + Nivolumab + Tocilizumab A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Active, not recruiting USA 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN 2
NCT03980041 Phase II Nivolumab Eganelisib + Nivolumab Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Completed USA | ITA | FRA | ESP 3
NCT02781506 Phase II Nivolumab Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer Terminated USA 0
NCT02720484 Phase II Nivolumab Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated USA 0
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 23
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Completed USA 0
NCT03959761 Phase Ib/II Nivolumab Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) Unknown status FRA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT02716948 Phase I Nivolumab Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Completed USA 0
NCT03595124 Phase II Nivolumab Axitinib + Nivolumab Axitinib A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) Active, not recruiting USA 1
NCT02919683 Phase II Nivolumab Ipilimumab + Nivolumab Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting USA 0
NCT02576509 Phase III Nivolumab Sorafenib A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT04758949 Phase II Nivolumab FL-101 + Nivolumab FL-101 FL-101 in Surgically Resectable Non-Small Cell Lung Cancer Withdrawn 0
NCT04957615 Phase II Nivolumab Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Recruiting USA 0
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT03899155 FDA approved Nivolumab Pan Tumor Nivolumab Rollover Study Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 28
NCT03355560 Phase II Nivolumab Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Active, not recruiting USA 0
NCT03878979 Phase II Nivolumab Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage Completed USA 0
NCT02652455 Phase I Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma Completed USA 0
NCT06295159 Phase I Nivolumab Nivolumab and relatlimab-rmbw Ipilimumab + Nivolumab Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Recruiting USA 0
NCT05681780 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Recruiting USA 0
NCT03383458 Phase III Nivolumab A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT03383302 Phase Ib/II Nivolumab SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) Active, not recruiting GBR 0
NCT04021420 Phase Ib/II Nivolumab Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (SONIMEL01) Unknown status FRA 0
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Active, not recruiting USA 0
NCT04785820 Phase II RO7121661 Nivolumab RO7247669 A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus Active, not recruiting ITA | GBR | FRA | ESP 14
NCT02060188 Phase Ib/II Nivolumab Ipilimumab A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 1
NCT02519322 Phase II Ipilimumab Nivolumab Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma Completed USA 0
NCT04099251 Phase III Nivolumab Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT02466568 Phase Ib/II Nivolumab Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Withdrawn 0
NCT03247712 Phase Ib/II Nivolumab Neoadjuvant Immunoradiotherapy in Head & Neck Cancer Active, not recruiting USA 0
NCT02823574 Phase II Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA | ITA | GBR | FRA | ESP | CAN | BEL 14
NCT03544723 Phase II Nivolumab Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Ad-p53 in Head and Neck Cancer Unknown status USA 0
NCT03656627 Phase I Nivolumab Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Terminated USA 0
NCT05188118 Phase I Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma Recruiting USA 0
NCT03329846 Phase III Linrodostat + Nivolumab Nivolumab An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT03335540 Phase I Linrodostat + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Completed USA 0
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed USA | CAN 0
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Active, not recruiting USA 0
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT02726581 Phase III Elotuzumab Nivolumab Dexamethasone + Pomalidomide Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma Completed USA | ITA | ESP | DEU | CAN | AUT 10
NCT02864316 Phase II Nivolumab Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure Terminated USA 0
NCT04901988 Phase II Nivolumab Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) Terminated GBR 0
NCT03025256 Phase I Nivolumab Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) Active, not recruiting USA 0
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Active, not recruiting ITA 0
NCT04209114 Phase III Nivolumab + NKTR-214 Nivolumab A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT04500548 Phase I Nivolumab Ipilimumab + Nivolumab Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Withdrawn USA | CAN 0
NCT03134118 Phase II Nivolumab Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM) Active, not recruiting GBR | FRA | ESP | BEL 2
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting USA | CAN 0
NCT04495010 Phase II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) Withdrawn USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT04008030 Phase III Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed USA 0
NCT02275533 Phase II Nivolumab Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy Active, not recruiting USA | CAN 0
NCT02105636 Phase III Methotrexate Cetuximab Docetaxel Nivolumab Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 8
NCT02631746 Phase II Nivolumab Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Completed USA 0
NCT02156804 Phase II Nivolumab A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) Completed ITA | GBR | ESP | DEU | BEL | AUT 14
NCT02750514 Phase II Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) Terminated USA | ITA | FRA | ESP | CAN | AUT | AUS 1
NCT02924233 Phase Ib/II Nivolumab + SYM004 Nivolumab Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Withdrawn 0
NCT05297565 Phase III Nivolumab BMS-986298 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE) Completed USA | ITA | GBR | ESP | BEL | AUS 1
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA | ITA | FRA | BEL 2
NCT03803553 Phase III Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Recruiting USA 0
NCT06275360 Phase II Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) Recruiting USA 0
NCT02439450 Phase I HS-110 Nivolumab A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Completed USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT03110978 Phase II Nivolumab Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR Active, not recruiting USA 0
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT02565758 Phase I Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors Completed USA | FRA | ESP 0
NCT03126331 Phase II Nivolumab Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients Completed USA 0
NCT03436862 Phase II Nivolumab Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression Completed USA 0
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting USA 0
NCT03532451 Phase I Lirilumab + Nivolumab Nivolumab Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) Completed USA 0
NCT02483247 Phase Ib/II Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Completed USA | CAN 0
NCT04526730 Phase II Nivolumab + Tavokinogene telseplasmid Nivolumab Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients Active, not recruiting USA 0
NCT04620603 Phase Ib/II Nivolumab Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Recruiting USA 0
NCT04801966 Phase 0 Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) Terminated AUS 0
NCT03521570 Phase II Nivolumab Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Active, not recruiting USA 0
NCT03107182 Phase II Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel Carboplatin + Nab-paclitaxel + Nivolumab Cisplatin Carboplatin + Nivolumab + Paclitaxel Nivolumab Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II) Active, not recruiting USA 0
NCT03651271 Phase II Ipilimumab + Nivolumab Nivolumab Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer Completed USA 0
NCT04674683 Phase III Nivolumab Chidamide + Nivolumab Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 8
NCT04268888 Phase II Nivolumab Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3) Recruiting GBR 0
NCT02538666 Phase III Ipilimumab Nivolumab A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT02481830 Phase III Amrubicin Nivolumab Topotecan Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 16
NCT04953104 Phase II Nivolumab Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Recruiting USA 0
NCT03807765 Phase I Nivolumab Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases Active, not recruiting USA 0
NCT03812562 Phase I Nivolumab Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection Terminated USA 0
NCT02664181 Phase II Nivolumab Decitabine + Nivolumab + Tetrahydrouridine Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) Active, not recruiting USA 0
NCT03316274 Phase I Nivolumab Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Completed USA 0
NCT04929028 Phase II Capecitabine + Mitomycin C Nivolumab Fluorouracil + Mitomycin C Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Recruiting USA 0
NCT03520491 Phase II Ipilimumab + Nivolumab Nivolumab A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Recruiting USA 0
NCT06029270 Phase II Carboplatin + Gemcitabine + Nivolumab Nivolumab Nivolumab + Relatlimab Cisplatin + Gemcitabine + Nivolumab Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Recruiting USA 0
NCT03371381 Phase Ib/II JNJ-64041757 + Nivolumab Nivolumab An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung Terminated USA | ESP | BEL 0
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Active, not recruiting USA 0
NCT03527108 Phase II Nivolumab + Ramucirumab Nivolumab Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Recruiting USA 0
NCT04697576 Phase I Nivolumab Pembrolizumab Ipilimumab Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma Recruiting USA 0
NCT02598960 Phase Ib/II Nivolumab BMS-986156 A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Terminated USA 0
NCT02181738 Phase II Nivolumab Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205) Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT 2
NCT06237920 Phase II Nivolumab Nivolumab + Relatlimab Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA) Recruiting 1
NCT03106610 Phase I Nivolumab Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy Terminated USA 0
NCT02575222 Phase I Nivolumab Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma Completed USA 0
NCT03307616 Phase II Ipilimumab + Nivolumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT02529072 Phase I Nivolumab Nivolumab With DC Vaccines for Recurrent Brain Tumors Completed USA 0
NCT03437200 Phase II Nivolumab Ipilimumab + Nivolumab Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) Terminated FRA | ESP 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT05987241 Phase II Nivolumab Nivolumab + Relatlimab Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Recruiting USA 0
NCT06116461 FDA approved Nivolumab Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE) Recruiting 1
NCT04567615 Phase II Nivolumab Nivolumab + Relatlimab A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Active, not recruiting FRA | ESP 15
NCT02829918 Phase II Nivolumab Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Completed USA 0
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Completed USA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT03171025 Phase II Nivolumab Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) Active, not recruiting USA 0
NCT04401774 Phase II Nivolumab Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy Active, not recruiting USA 0
NCT03519256 Phase II Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) Terminated USA | ITA | GBR | FRA | ESP | CAN | AUS 8
NCT03591731 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) Active, not recruiting FRA 0
NCT02967133 Phase II Nab-paclitaxel + Nivolumab Nivolumab A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Terminated USA 0
NCT03690986 Phase I Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer Recruiting USA 0
NCT04095208 Phase II Nivolumab + Relatlimab Nivolumab Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (CONGRATS) Recruiting FRA 0
NCT02596035 FDA approved Nivolumab A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) Completed USA 0
NCT02142218 Phase I Nivolumab Expanded Access Program With Nivolumab to Treat Melanoma No longer available USA | CAN 4
NCT02962804 Phase II Nivolumab Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) Withdrawn USA 0
NCT02569242 Phase III Docetaxel + Paclitaxel Nivolumab Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed USA | ITA | GBR | DEU 4
NCT03727061 Phase II Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Recruiting USA 0
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Recruiting USA 1
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Completed USA | GBR | FRA | ESP | DEU | BEL 5
NCT02617589 Phase III Nivolumab Temozolomide Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT03495713 Phase II Nivolumab RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS Terminated USA 0
NCT04013854 Phase II Ipilimumab + Nivolumab Nivolumab Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab Recruiting USA 0
NCT03168464 Phase Ib/II Nivolumab Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Terminated USA 0
NCT02423954 Phase Ib/II Temsirolimus Nivolumab Capecitabine Irinotecan Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) Terminated USA 0
NCT04410445 Phase III Nivolumab Nivolumab + NKTR-214 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) Terminated USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 9
NCT03325816 Phase Ib/II Nivolumab Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed USA 0
NCT03233711 Phase II Nivolumab Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Active, not recruiting USA | CAN 0
NCT05743270 Phase II Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN Withdrawn USA | GBR | FRA | ESP | DEU 3
NCT05817903 Phase II Nivolumab Axitinib + Nivolumab Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR (AxIn) Recruiting ITA 0
NCT02684253 Phase II Nivolumab Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed USA 0
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Withdrawn 0
NCT01585194 Phase II Ipilimumab Nivolumab Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma Active, not recruiting USA 0
NCT04401995 Phase II Nivolumab Nivolumab + Vidutolimod Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab Suspended USA 0
NCT04648319 Phase II Nivolumab A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Terminated BEL 2
NCT04090710 Phase II Nivolumab Ipilimumab + Nivolumab SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) Recruiting CAN | AUS 0
NCT03355976 Phase II Ipilimumab + Nivolumab Nivolumab BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Active, not recruiting USA 0
NCT02469701 Phase II Nivolumab BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease Terminated USA 0
NCT03421652 Phase II Nivolumab Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy Completed USA 0
NCT05002569 Phase III Nivolumab + Relatlimab Nivolumab A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT02339558 Phase II Nivolumab Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer Completed USA 2
NCT02829931 Phase I Nivolumab Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas Completed USA 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02599402 Phase III Ipilimumab + Nivolumab Nivolumab Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed ITA | GBR | FRA | DEU | BEL | AUT | AUS 5
NCT04026412 Phase III Nivolumab Ipilimumab + Nivolumab Durvalumab A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT05112601 Phase II Ipilimumab + Nivolumab Nivolumab Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Recruiting USA 0
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Terminated USA 0
NCT02599649 Phase II Nivolumab Azacitidine Lirilumab Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) Terminated USA 0
NCT06059547 Phase II Nivolumab CTL-002 + Nivolumab Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Recruiting ITA 0
NCT03382912 Phase II Nivolumab + Pegilodecakin Nivolumab Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) Terminated USA 0
NCT04106414 Phase II Nivolumab Linrodostat + Nivolumab Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Active, not recruiting USA 0
NCT04913025 Phase II Pembrolizumab Nivolumab REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) Recruiting GBR 0
NCT03016871 Phase II Nivolumab Carboplatin + Etoposide + Ifosfamide + Nivolumab Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Active, not recruiting USA 0
NCT04295863 Phase I Nivolumab Pembrolizumab Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers Recruiting USA 0
NCT02259231 Phase Ib/II Ipilimumab Nivolumab Omaveloxolone RTA 408 Capsules in Patients With Melanoma - REVEAL Completed USA 0
NCT03704077 Phase II Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma Withdrawn USA | ITA | ESP | DEU | CAN | AUS 8
NCT03258567 Phase II Nivolumab Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas Recruiting USA 0
NCT01928576 Phase II Nivolumab Entinostat Azacitidine Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. Completed USA 0
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Terminated USA 0
NCT03496662 Phase Ib/II Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Active, not recruiting USA 0
NCT05846659 Phase II Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies Recruiting USA 0
NCT03776487 Phase Ib/II Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Active, not recruiting USA 0
NCT02210117 Phase II Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) Active, not recruiting USA 0
NCT04080804 Phase II Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Recruiting USA 0
NCT02857426 Phase II Nivolumab A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647) Completed USA | ITA | FRA | DEU | CAN 8
NCT03080974 Phase II Nivolumab Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Recruiting USA 0
NCT03952585 Phase II Nivolumab Cisplatin De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Suspended USA | CAN 0
NCT02614456 Phase I Nivolumab Interferon gamma Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors Completed USA 0
NCT02518958 Phase I Nivolumab A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab Completed USA 0
NCT02428192 Phase II Nivolumab Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma Active, not recruiting USA 0
NCT03604991 Phase II Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma Suspended USA 0
NCT02832167 Phase II Nivolumab An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (CheckMate 627) Completed USA | DEU 0
NCT04205552 Phase II Nivolumab + Relatlimab Nivolumab Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict) Recruiting DEU | BEL 1
NCT04400539 Phase II Nivolumab The IMmunotherapy Pleural 5-ALA PDT (IMPALA) Recruiting FRA 0
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT03743662 Phase II Nivolumab Bevacizumab Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Active, not recruiting USA 0
NCT03487666 Phase II Capecitabine + Nivolumab Capecitabine Nivolumab OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Active, not recruiting USA 0
NCT04866654 Phase II Nivolumab Radiation Free Chemotherapy for Early Hodgkin Lymphoma (RAFTING) Recruiting ITA | ESP 1
NCT04464759 Phase Ib/II Nivolumab Hydroxychloroquine + Ipilimumab + Nivolumab Hydroxychloroquine + Nivolumab A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT) Recruiting USA 0
NCT03023904 Phase II Nivolumab Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Withdrawn 0
NCT02648997 Phase II Nivolumab A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting USA 0
NCT02731729 Phase II Ipilimumab Nivolumab Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy Completed USA 0
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Terminated USA 0
NCT04387084 Phase I Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Recruiting USA 0
NCT04309409 Phase III Nivolumab Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela) Active, not recruiting DEU 0
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting 1
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Terminated USA 0
NCT02259621 Phase II Nivolumab Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC Active, not recruiting USA | CAN 0
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT04149275 Phase II Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma Withdrawn USA 0
NCT03195491 Phase III Nivolumab A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) Completed 2
NCT02066636 Phase III Nivolumab A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) Completed USA | CAN 0
NCT02737475 Phase Ib/II Ipilimumab BMS-986178 Nivolumab Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors Completed USA | ITA | ESP | CAN 2
NCT03703050 Phase II Nivolumab Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL) Recruiting FRA 2
NCT04658147 Phase I Nivolumab + Relatlimab Nivolumab Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT04123379 Phase II BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Active, not recruiting USA 0
NCT03685890 Phase Ib/II Nivolumab Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NivoILP) Recruiting 2
NCT02764593 Phase I Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02426892 Phase II Nivolumab Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors Completed USA 0
NCT03311958 Phase I Nivolumab Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance Active, not recruiting USA 0
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Active, not recruiting USA 0
NCT02038946 Phase II Nivolumab Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02880020 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02992964 Phase Ib/II Nivolumab Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers Terminated USA | FRA | CAN | AUS 1
NCT02194738 Phase I Nivolumab Crizotinib Erlotinib Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting USA 2
NCT03854032 Phase II Nivolumab Linrodostat + Nivolumab Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Active, not recruiting USA 0
NCT03718767 Phase II Nivolumab Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Recruiting USA 0
NCT02532231 Phase II Nivolumab Nivolumab in AML in Remission at High Risk for Relapse Completed USA 0
NCT03122522 Phase II Nivolumab Ipilimumab + Nivolumab A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy Active, not recruiting USA 0
NCT04159818 Phase II Nivolumab Doxorubicin + Nivolumab Cisplatin + Nivolumab Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2) Recruiting 1
NCT05907122 Phase III Nivolumab A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Resected Melanoma Recruiting USA | ITA | FRA | ESP | DEU 15
NCT03038672 Phase II Nivolumab + Varlilumab Nivolumab Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting USA 0
NCT03811015 Phase II Cisplatin Nivolumab Cisplatin + Nivolumab Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer Recruiting USA 0
NCT03521830 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Recruiting USA 0
NCT04848116 Phase II Cabiralizumab + Nivolumab BMS-986253 + Nivolumab Nivolumab Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2) Recruiting USA 0
NCT03906526 Phase I Motolimod Motolimod + Nivolumab Nivolumab A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer Terminated USA 0
NCT03367741 Phase II Cabozantinib + Nivolumab Nivolumab Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT03425292 Phase I Temozolomide Ipilimumab + Nivolumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Completed USA 0
NCT02595918 Phase I Nivolumab Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer Terminated USA 0
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Active, not recruiting USA 0
NCT02530463 Phase II Nivolumab Azacitidine Ipilimumab Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Active, not recruiting USA 0
NCT03117309 Phase II Ipilimumab + Nivolumab Nivolumab Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Active, not recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03815890 Phase II Nivolumab Ipilimumab + Nivolumab Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI) Recruiting 1
NCT03715946 Phase II Nivolumab Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Active, not recruiting USA 0
NCT03631641 Phase II Nivolumab Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Active, not recruiting USA 0
NCT04134325 Phase I Nivolumab Pembrolizumab Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03245021 Phase I Nivolumab + Rituximab Nivolumab Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR) Active, not recruiting AUS 0
NCT02989636 Phase I Nivolumab Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Active, not recruiting USA 0
NCT02388906 Phase III Nivolumab Ipilimumab Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 16
NCT02472977 Phase Ib/II Nivolumab Ulocuplumab Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Terminated USA 1
NCT02595944 Phase III Nivolumab Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) Active, not recruiting USA 0
NCT04042753 Phase II Ipilimumab + Nivolumab Nivolumab Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Active, not recruiting USA 0
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Completed USA 0
NCT02837029 Phase I Nivolumab Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT03149120 Phase II Nivolumab Nivolumab + Pazopanib Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Withdrawn USA 0
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed USA 0
NCT04462406 Phase II Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Recruiting USA 0
NCT03522246 Phase III Rucaparib Nivolumab Nivolumab + Rucaparib A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 16
NCT05465174 Phase II Nivolumab + Tovorafenib Tovorafenib Nivolumab Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029) Recruiting USA 0
NCT05846646 Phase II Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Recruiting USA 0
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Active, not recruiting USA 0
NCT03879811 Phase II Nivolumab Temozolomide Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer Withdrawn 0
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Active, not recruiting CAN 0
NCT02421354 Phase II Nivolumab Study of Nivolumab in Patients With Myelofibrosis Terminated USA 0
NCT05496192 Phase II Nivolumab BMS-986298 A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer Withdrawn ESP | DEU 0
NCT03980314 Phase Ib/II Nivolumab A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection Completed USA | ITA | FRA | ESP | CAN | AUS 8
NCT03203473 Phase II Nivolumab Ipilimumab + Nivolumab Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Active, not recruiting USA 0
NCT05652673 FDA approved Nivolumab Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial Recruiting 1
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Active, not recruiting USA 0
NCT03576612 Phase I AdV-tk Temozolomide Valacyclovir Nivolumab GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI) Active, not recruiting USA 0
NCT04340193 Phase III Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10


Additional content available in CKB BOOST